通过CRISPR条形码对肿瘤内异质性进行建模。
Modeling intratumor heterogeneity through CRISPR-barcodes.
作者信息
Guernet Alexis, Aaronson Stuart A, Anouar Youssef, Grumolato Luca
机构信息
Normandie Univ, UNIROUEN, INSERM, DC2N, Rouen, France; Institute for Research and Innovation in Biomedicine, Rouen, France.
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai , New York, NY, USA.
出版信息
Mol Cell Oncol. 2016 Sep 6;3(6):e1227894. doi: 10.1080/23723556.2016.1227894. eCollection 2016.
Abstract
We have devised a barcoding strategy to recapitulate cancer evolution through the emergence of subclonal mutations of interest, whose effects can be monitored in a dynamic manner. This approach can be easily adapted for a variety of applications, including combined modeling of multiple mechanisms of drug resistance or repair of oncogenic driver mutations in addicted cancer cells.
摘要
我们设计了一种条形码策略，通过感兴趣的亚克隆突变的出现来重现癌症进化，其效果可以动态监测。这种方法可以很容易地应用于各种场景，包括对多种耐药机制的联合建模或成瘾癌细胞中致癌驱动突变的修复。
相似文献
1
Modeling intratumor heterogeneity through CRISPR-barcodes.通过CRISPR条形码对肿瘤内异质性进行建模。
Mol Cell Oncol. 2016 Sep 6;3(6):e1227894. doi: 10.1080/23723556.2016.1227894. eCollection 2016.
2
CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.用于肿瘤内基因异质性建模和致癌驱动基因突变功能分析的CRISPR条形码技术
Mol Cell. 2016 Aug 4;63(3):526-38. doi: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21.
3
Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.多区域测序揭示了TP53驱动的非小细胞肺癌中驱动基因突变的肿瘤内异质性。
Int J Cancer. 2017 Jan 1;140(1):103-108. doi: 10.1002/ijc.30437. Epub 2016 Oct 3.
4
Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.混合性肺腺癌中ALK重排的肿瘤内异质性及EGFR突变的同质性
PLoS One. 2015 Sep 30;10(9):e0139264. doi: 10.1371/journal.pone.0139264. eCollection 2015.
5
The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.TP53突变对早期非小细胞肺癌患者预后的影响可能取决于突变的肿瘤内异质性。
Mol Carcinog. 2015 Feb;54(2):93-101. doi: 10.1002/mc.22077. Epub 2013 Sep 4.
6
Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.结直肠癌患者中的低频KRAS突变以及非小细胞肺癌患者致癌驱动基因中的多重突变。
Cancer Genet. 2013 Sep-Oct;206(9-10):330-9. doi: 10.1016/j.cancergen.2013.09.004. Epub 2013 Oct 2.
7
CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.非小细胞肺癌中的CRISPR条形码技术：从肿瘤内基因异质性建模到癌症治疗应用
J Thorac Dis. 2017 Jul;9(7):1759-1762. doi: 10.21037/jtd.2017.06.27.
8
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.非小细胞肺癌中靶向治疗的耐药机制
Handb Exp Pharmacol. 2018;249:63-89. doi: 10.1007/164_2017_16.
9
Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.通过CRISPR/Cas9对致癌突变等位基因进行选择性破坏可有效诱导肿瘤消退。
Nucleic Acids Res. 2017 Jul 27;45(13):7897-7908. doi: 10.1093/nar/gkx490.
10
Who Is in the Driver's Seat: Tracing Cancer Genes Using CRISPR-Barcoding.谁在掌控局面：使用 CRISPR 条形码追踪癌症基因。
Mol Cell. 2016 Aug 4;63(3):352-4. doi: 10.1016/j.molcel.2016.07.013.
引用本文的文献
1
Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update.CRISPR/Cas技术在耐药性肺癌治疗中的应用：最新进展
Mol Biol Rep. 2022 Dec;49(12):11491-11502. doi: 10.1007/s11033-022-07766-7. Epub 2022 Sep 12.
2
Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells.突变等位基因定量分析揭示了前列腺癌细胞中 TP53 突变驱动的去势抵抗的遗传基础。
Sci Rep. 2018 Aug 21;8(1):12507. doi: 10.1038/s41598-018-30062-z.
本文引用的文献
1
CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.用于肿瘤内基因异质性建模和致癌驱动基因突变功能分析的CRISPR条形码技术
Mol Cell. 2016 Aug 4;63(3):526-38. doi: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21.
2
Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells.条形码揭示了新转化的人类乳腺细胞的复杂克隆动力学。
Nature. 2015 Dec 10;528(7581):267-71. doi: 10.1038/nature15742. Epub 2015 Dec 2.
3
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.利用高复杂度条形码研究癌症治疗反应中的克隆动力学。
Nat Med. 2015 May;21(5):440-8. doi: 10.1038/nm.3841. Epub 2015 Apr 13.
4
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution.肿瘤内异质性在癌症进化中的生物学和治疗影响。
Cancer Cell. 2015 Jan 12;27(1):15-26. doi: 10.1016/j.ccell.2014.12.001.
5
Genome editing. The new frontier of genome engineering with CRISPR-Cas9.基因组编辑。CRISPR-Cas9 技术引领的基因组工程新前沿。
Science. 2014 Nov 28;346(6213):1258096. doi: 10.1126/science.1258096.
6
Development and applications of CRISPR-Cas9 for genome engineering.用于基因组工程的CRISPR-Cas9技术的开发与应用。
Cell. 2014 Jun 5;157(6):1262-1278. doi: 10.1016/j.cell.2014.05.010.
7
Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease.全基因组分析揭示 Cas9 内切酶结合的脱靶位点特征。
Nat Biotechnol. 2014 Jul;32(7):677-83. doi: 10.1038/nbt.2916. Epub 2014 May 18.
8
Tumor heterogeneity confounds and illuminates: assessing the implications.肿瘤异质性既带来了困惑，也带来了启示：评估其影响。
Nat Med. 2014 Apr;20(4):342-4. doi: 10.1038/nm.3522.
9
Genome engineering using the CRISPR-Cas9 system.使用 CRISPR-Cas9 系统进行基因组工程。
Nat Protoc. 2013 Nov;8(11):2281-2308. doi: 10.1038/nprot.2013.143. Epub 2013 Oct 24.
10
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells.CRISPR-Cas 核酸酶在人类细胞中诱导的高频脱靶突变。
Nat Biotechnol. 2013 Sep;31(9):822-6. doi: 10.1038/nbt.2623. Epub 2013 Jun 23.
Zotero 插件